

Criteria Grid
Best Practices and Interventions for the Diagnosis and Treatment of Hepatitis C

Best Practice/Intervention:	Carrat et al. (2004). Study to evaluate the safety and efficacy of peginterferon alfa-2b plus ribavirin vs standard interferon alfa-2b plus ribavirin in HIV-HCV coinfecting patient. A randomized control trial. JAMA, 292(23), 2839-2848.			
Date of Review:	May 23 2011			
Reviewer(s):	Andrea Fisher			
Part A				
Category:	Basic Science <input type="checkbox"/> Clinical Science <input checked="" type="checkbox"/> Public Health/Epidemiology <input type="checkbox"/> Social Science <input type="checkbox"/> Programmatic Review <input type="checkbox"/>			
Best Practice/Intervention:	Focus: Hepatitis C <input type="checkbox"/> Hepatitis C/HIV X Other: _____ Level: Group X Individual <input type="checkbox"/> Other: _____ Target Population: <u>HIC-HCV Coinfected Patients</u> Setting: Health care setting/Clinic X Home <input type="checkbox"/> Other: _____ Country of Origin: <u>France</u> Language: English <input checked="" type="checkbox"/> French <input type="checkbox"/> Other: _____			
Part B				
	YES	NO	N/A	COMMENTS
<i>Is the best practice/intervention a meta-analysis or primary research?</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Primary Research, Efficacy Study
<i>The best practice/intervention has utilized an evidence-based approach to assess:</i>				
<i>Efficacy</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	
<i>Effectiveness</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
<i>The best practice/intervention has been evaluated in more than one patient setting to assess:</i>				

<i>Efficacy</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	71 French Centres
<i>Effectiveness</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	
	YES	NO	N/A	COMMENTS
<i>The best practice/intervention has been operationalized at a multi-country level:</i>				
<i>There is evidence of capacity building to engage individuals to accept treatment/diagnosis</i>	<input type="checkbox"/>	<input type="checkbox"/>	X	This is a randomized controlled trial.
<i>There is evidence of outreach models and case studies to improve access and availability</i>	<input type="checkbox"/>	<input type="checkbox"/>	X	This is a randomized controlled trial.
<i>Do the methodology/results described allow the reviewer(s) to assess the generalizability of the results?</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	Details describing the methodology and study results are reported.
<i>Are the best practices/methodology/results described applicable in developed countries?</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<i>Evidence of manpower requirements is indicated in the best practice/intervention</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Health care professionals, clinic setting, drug therapy program
<i>Juried journal reports of this treatment, intervention, or diagnostic test have occurred</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	Published in JAMA; peer reviewed; several follow-up studies; APRICOT Study
<i>International guideline or protocol has been established</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Study protocol developed
<i>The best practice/intervention is easily accessed/available electronically</i>	X	<input type="checkbox"/>	<input type="checkbox"/>	Downloaded from jama.ama-assn.org
<i>Is there evidence of a cost effective analysis? If so, what does the evidence say?</i> Please go to Comments section	<input type="checkbox"/>	X	<input type="checkbox"/>	No reported cost effective analysis
<i>How is the best practice/intervention funded?</i> Please got to Comments section	X	<input type="checkbox"/>	<input type="checkbox"/>	Grant from Agence Nationale de Recherches sur le SIDA, a publicly funded agency involved in clinical research on HIV and HCV. Funded in Canada
<i>Other relevant criteria:</i> Notable Findings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Drugs provided by Schering-Plough. Data analysis was performed by the sponsor and the authors, both of whom were independent of the drug manufacturer. Dose of ribovirian was small. Likely better outcomes if the dose was larger.